STOCK TITAN
  1. Home
  2. News
  3. CODX

Co-Diagnostics Inc - CODX STOCK NEWS

Welcome to our dedicated news page for Co-Diagnostics (Ticker: CODX), a resource for investors and traders seeking the latest updates and insights on Co-Diagnostics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Co-Diagnostics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Co-Diagnostics's position in the market.

News
Co-Diagnostics, Inc. Announces First Quarter 2024 Earnings Release Date and Webcast
Rhea-AI Summary
Co-Diagnostics, Inc. (CODX) announced the release date for its first-quarter 2024 financial results, scheduled for May 9, 2024. The company will host a conference call and webcast to discuss the financial results with analysts and institutional investors. Management team members including CEO Dwight Egan, CFO Brian Brown, and Head of Investor Relations Andrew Benson will participate in the call.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
earnings
-
News
Co-Diagnostics, Inc. to Host Booth and Deliver Presentation at APRC 2024 in Taiwan
Rhea-AI Summary
Co-Diagnostics, Inc. (Nasdaq: CODX) will host a booth and present at APRC 2024 in Taiwan. The conference focuses on holistic healthcare and tackling communicable diseases like tuberculosis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.87%
Tags
conferences
-
News
Co-Diagnostics, Inc. Inaugurates New Manufacturing Facility in Utah with Ribbon Cutting Event
Rhea-AI Summary
Co-Diagnostics, Inc. (CODX) inaugurates a new manufacturing facility in South Salt Lake, supported by Mayor Wood and other dignitaries. The facility will produce the Co-Dx Pro™ instrument, test cups, and patented Co-Primers™ chemistry for PCR diagnostic tests, aiming to enhance global access to high-quality diagnostics.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.23%
Tags
none
News
Co-Diagnostics, Inc. Appoints New President and Other C-Level Positions
Rhea-AI Summary
Co-Diagnostics, Inc. (CODX) appoints Richard Abbott as President, David Nielsen as COO, Christopher Thurston as CTO, and Seth Egan as CCO. The new leadership team brings extensive experience in diagnostics and technology to drive the development and commercialization of the Co-Dx PCR platform and associated tests.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.68%
Tags
management
-
News
Co-Diagnostics, Inc. CEO Delivers Manufacturing and Commercialization Update in Conference Keynote Address
Rhea-AI Summary
Co-Diagnostics, Inc. announces the opening of a new manufacturing facility in Salt Lake City, UT, and provides updates on facilities in India. The Company CEO shared plans for in-house manufacturing of key reagent components and equipment for their new PCR platform, aiming for commercialization. The Company focuses on addressing diseases like TB, aligning with global health organizations' missions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.36%
Tags
none
-
News
Co-Diagnostics, Inc. Reports Full Year 2023 Financial Results
Rhea-AI Summary
Co-Diagnostics, Inc. (CODX) reported full-year 2023 financial results, with revenue at $6.8 million, a decrease from $34.2 million in the prior year due to lower demand for COVID-19 tests. Operating expenses decreased to $45.3 million, resulting in an operating loss of $42.7 million. The company reported a net loss of $35.3 million, with an adjusted EBITDA loss of $33.0 million. Despite challenges, Co-Diagnostics achieved key milestones, including clinical evaluations, FDA EUA submissions, and grant funding for test development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.08%
Tags
earnings
News
Co-Diagnostics, Inc. JV CoSara Receives Clearance from Indian Regulators for Influenza Multiplex PCR Test
Rhea-AI Summary
Co-Diagnostics, Inc. announces CDSCO clearance for CoSara's SARAPLEX Influenza Multiplex Test Kit, expanding CoSara's IVD test portfolio in India. The test utilizes Co-Primers technology to detect and differentiate various influenza strains, enhancing accurate PCR testing in clinical labs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.87%
Tags
none
-
News
Co-Diagnostics, Inc. Announces Fourth Quarter and Full Year 2023 Earnings Release Date and Webcast
Rhea-AI Summary
Co-Diagnostics, Inc. (CODX) will release its Q4 and full-year 2023 financial results on March 14, 2024. The company will host a conference call with key executives to discuss the results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.8%
Tags
earnings
-
News
Co-Diagnostics, Inc. Shares List of Upcoming Industry Conferences and Events for February 2024
Rhea-AI Summary
Co-Diagnostics, Inc. (CODX) announces its participation in key events to showcase its Co-Dx PCR platform technology and upcoming diagnostic tests. The events include a workshop in India, a medical lab exhibition in Dubai, a life sciences event in Utah, and a global conference on respiratory diseases in India. The company's joint venture in India will present its innovative TB diagnostic test, and the company is exploring registrations in Saudi Arabia. The Co-Dx PCR platform and COVID-19 test are currently under FDA review.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.2%
Tags
none
News
Co-Diagnostics, Inc. to Host Booth at CES 2024 January 9-12
Rhea-AI Summary
Co-Diagnostics, Inc. (Nasdaq-CM: CODX) will be showcasing its Co-Dx PCR at-home and point-of-care platform at the 2024 Consumer Electronics Show. The Company has submitted its Co-Dx PCR Pro™ and COVID-19 test to the FDA for Emergency Use Authorization.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.82%
Tags
conferences
Stock CODX logo
Co-Diagnostics Inc

Nasdaq:CODX

CODX Rankings

#4928 Ranked by Market Cap
#5113 Ranked by Stock Gains
N/A Ranked by Dividends

CODX Stock Data

37.51M
30.41M
2.68%
15.77%
1.59%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
US
Salt Lake City

About CODX

co-diagnostics, inc. is a molecular diagnostics company that has acquired certain unique, patented diagnostic testing technology. a utah corporation headquartered in sandy, utah, its primary business is to commercialize its unique, patented technology through sales, development and licensing. the technology is embodied in three patent applications and certain trade secrets, which make dna testing for diseases faster, higher in performance, and more cost efficient than traditional technologies of the past. the company has undertaken completely innovative approaches to develop novel molecular technologies using biophysical models and statistical bioinformatics. it has successfully developed and commercialized a series of assays in the infectious disease area to demonstrate the capability of its technology. the technology on which the inventions are based were created by reference to certain mathematical models invented, designed and refined by dr. brent c. satterfield. the inventions are